Mexico - Delayed Quote MXN

AbbVie Inc. (ABBV.MX)

3,559.63

+65.63

+(1.88%)

At close: May 28 at 1:56:14 PM CST

AbbVie Inc. (ABBV)’s Pipeline Advances with Temab-A and ABBV-706, Shares Flat

AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective response rate in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) patients, with over half maintaining their response […]

Insider Monkey 2 hours ago

ABBV
AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers

AbbVie (NYSE:ABBV) recently unveiled promising data on its investigational therapies, including the novel c-Met-targeting ADC, Temab-A, and the SEZ6-directed ADC, ABBV-706, indicating progress in their clinical pipelines. Despite these announcements, AbbVie's stock price remained flat, aligned with overall market stability. The market awaited significant financial updates, such as Nvidia's anticipated earnings report, contributing to a general holding pattern in stock movements. While...

Simply Wall St. 12 hours ago

ABBV
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Zacks 17 hours ago

ABBV
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

AbbVie (NYSE: ABBV) today announced that key data from its broad oncology portfolio will be showcased across multiple oral presentations and posters at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3, 2025). These new data highlight significant progress in AbbVie's robust oncology pipeline, across a range of difficult-to-treat solid tumors and blood cancers.

PR Newswire yesterday

ABBV
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers.

StockStory 2 days ago

MYGN

BMRN

UTHR
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result

There's little doubt these pharmaceutical companies' costs will soon be rising at least a little.

Motley Fool 4 days ago

PFE

ABBV

AMGN
50 Huge Companies That You’ve Never Heard of Before and Their Stock Prices

You may think you know all of the wealthiest multinational companies, from Walmart to Apple to Amazon. But you might be surprised at how many companies with tens of billions in annual revenue you've...

GOBankingRates 5 days ago

ABBV

PSX
Key Drivers Behind AbbVie’s (ABBV) Performance

RS Investments, an investment management company, released its “RS Large Cap Value Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the strategy underperformed its benchmark, the Russell 1000 Value Index (the “Index”), and returned 1.57% (net) versus a return of 2.14% for the Index. […]

Insider Monkey 5 days ago

ABBV
AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit

AbbVie Inc. (NYSE:ABBV) has achieved a significant legal victory as the Illinois Appellate Court upheld the dismissal of a shareholder class action lawsuit stemming from its $63 billion acquisition of Allergan plc in 2020. The lawsuit, led by plaintiff Stephen Twigg on behalf of former U.S.-based Allergan shareholders, accused ABBV of improperly issuing unregistered shares […]

Insider Monkey 6 days ago

ABBV
AbbVie (NYSE:ABBV) Faces Legal Scrutiny Over Merger With Cerevel

AbbVie (NYSE:ABBV) experienced a 6.8% share price increase over the past month, coinciding with several significant corporate events. The company announced a collaboration with ADARx Pharmaceuticals to develop siRNA therapeutics, as well as FDA approval for EMRELIS™ in treating lung cancer, indicating strong product development. Additionally, AbbVie's stock buyback activity and board expansion added layers of positive momentum. Although the markets experienced a 1.1% decline driven by broader...

Simply Wall St. 6 days ago

ABBV
AbbVie and U of T Mississauga's SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient

AbbVie (NYSE: ABBV) in partnership with the University of Toronto's SpinUp, are pleased to announce Neuropeutics Inc as the recipient of the AbbVie Biotech Innovators Award, a national prize to help foster innovation and support growth in Canada's life sciences sector. Following a competitive selection process, the award, funded by AbbVie, has been granted to Neuropeutics Inc for developing small molecules preventing and reversing protein aggregation as therapeutics for neurodegenerative disease

CNW Group 6 days ago

ABBV
AbbVie (ABBV) has a Stable and Highly Profitable Business Model

Renaissance Investment Management, an investment management company, released its Q1 2025 “Large Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. The S&P 500 experienced a 4.3% loss in Q1 due to uncertainty in technology stock valuations and US economic policies. However, seven sectors showed positive returns, with Energy, Health […]

Insider Monkey 6 days ago

ABBV

^GSPC
3 Value Stocks Facing Headwinds

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

StockStory 7 days ago

ARW

ABBV

ASO
2 Incredible Dividend Growth Stocks to Buy Now

Dividend growth stocks often deliver returns that are superior to the benchmark S&P 500. AbbVie and W.W. Grainger are elite dividend growth stocks that would be solid additions to any income-focused portfolio. Historically, companies with 10-year annualized dividend growth rates above 6% have consistently outperformed the S&P 500.

Motley Fool 7 days ago

ABBV

GWW

^GSPC
AbbVie (ABBV) Soared on Favorable Tailwinds

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index ended Q1 down 4.3%, marking a turbulent start to 2025. The volatility that began in February was triggered by factors including policy […]

Insider Monkey 8 days ago

ABBV

^GSPC
Pfizer Signs Experimental Drug Licensing Agreement With 3SBio

Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.

Zacks 8 days ago

PFE

TRSBF

ABBV
The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie

Bayer, Novo Nordisk, GSK, Merck and AbbVie are part of the Zacks top Analyst Blog.

Zacks 9 days ago

ABBV

BAYN.DE

NVO
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.

Here are three dividend-paying stocks that warrant closer examination.

Motley Fool 10 days ago

PFE

MDT

ABBV
3 Magnificent Stocks That Are Passive Income Machines

Abbott Laboratories is a dividend stock you can buy and (almost) forget about. AbbVie has proved its resilience by becoming stronger after losing patent exclusivity for its blockbuster drug Humira. Johnson & Johnson is a seasoned dividend payer for all seasons.

Motley Fool 11 days ago

ABBV

JNJ

ABT
Jim Cramer On AbbVie: Makes “Sense To Start a Position in the Stock”

Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said: “Or how about one of my absolute favorites right here too, AbbVie. Now here’s a drug company with no patent cliff in sight whatsoever. Got tremendous franchises in neurology, oncology, immunology, and medical aesthetics, among others. Because […]

Insider Monkey 12 days ago

ABBV

Performance Overview

Return	ABBV.MX	S&P 500 (^GSPC)
YTD	-1.55%	+0.12%
1-Year	+35.60%	+10.98%
3-Year	+22.31%	+41.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AbbVie Inc. (ABBV.MX)

AbbVie Inc. (ABBV)’s Pipeline Advances with Temab-A and ABBV-706, Shares Flat

AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result

50 Huge Companies That You’ve Never Heard of Before and Their Stock Prices

Key Drivers Behind AbbVie’s (ABBV) Performance

AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit

AbbVie (NYSE:ABBV) Faces Legal Scrutiny Over Merger With Cerevel

AbbVie and U of T Mississauga's SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient

AbbVie (ABBV) has a Stable and Highly Profitable Business Model

3 Value Stocks Facing Headwinds

2 Incredible Dividend Growth Stocks to Buy Now

AbbVie (ABBV) Soared on Favorable Tailwinds

Pfizer Signs Experimental Drug Licensing Agreement With 3SBio

The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie

Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.

3 Magnificent Stocks That Are Passive Income Machines

Jim Cramer On AbbVie: Makes “Sense To Start a Position in the Stock”

Performance Overview